US Cancer Mortality Drops

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 15 No 6
Volume 15
Issue 6

Cancer remains the second leading cause of death in the United States, but the disease's mortality rate declined by 2.9% in 2004, according to the Centers for Disease Control and Prevention (CDC). Total US cancer deaths in 2004 numbered 550,270. Preliminary mortality data put the age-adjusted death rate for malignant neoplasms at 184.6 per 100,000 population, down from 190.1 in 2003. The nation's overall death rate fell to a record low of 801 per 100,000 persons, down from 833 the previous year. The preliminary data are based on approximately 90% of the 2004 death records reported by the 50 states.

WASHINGTON—Cancer remains the second leading cause of death in the United States, but the disease's mortality rate declined by 2.9% in 2004, according to the Centers for Disease Control and Prevention (CDC). Total US cancer deaths in 2004 numbered 550,270. Preliminary mortality data put the age-adjusted death rate for malignant neoplasms at 184.6 per 100,000 population, down from 190.1 in 2003. The nation's overall death rate fell to a record low of 801 per 100,000 persons, down from 833 the previous year. The preliminary data are based on approximately 90% of the 2004 death records reported by the 50 states.

Recent Videos
Approximately 95% of those with a complete response to enfortumab vedotin plus pembrolizumab were alive after 2 years in the phase 3 EV-302 trial.
According to Megan Mullins, PhD, MPH, challenging cultural norms surrounding death and dying may reduce the receipt of low-value end-of-life cancer care.
Thomas Powles, MBBS, MRCP, MD, highlighted fatigue, nausea, and peripheral neuropathy as toxicities observed with enfortumab vedotin plus pembrolizumab.
Earlier and more frequent talks about disabling ICDs with patients receiving end-of-life care and their families may help avoid excessive pain.
3 experts in this video
3 experts in this video
Large international meetings may facilitate conversations regarding disparities of care outside of high-income countries.
Related Content